

Michael S Kinch

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9067066/michael-s-kinch-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100
papers

5,657
citations

43
h-index

74
g-index

101
ext. papers

6,099
ext. citations

7.6
avg, IF

5.74
L-index

#	Paper	IF	Citations
100	Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. <i>Nature Cell Biology</i> , 2000 , 2, 62-9	23.4	455
99	An analysis of FDA-approved drugs: natural products and their derivatives. <i>Drug Discovery Today</i> , 2016 , 21, 204-7	8.8	389
98	Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia. <i>Journal of Cell Biology</i> , 1995 , 130, 461-71	7.3	266
97	EphA2 expression is associated with aggressive features in ovarian carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 5145-50	12.9	181
96	An overview of FDA-approved new molecular entities: 1827-2013. <i>Drug Discovery Today</i> , 2014 , 19, 1033-8	8.8	152
95	Dynamic interaction of PTPmu with multiple cadherins in vivo. <i>Journal of Cell Biology</i> , 1998 , 141, 287-96	7.3	152
94	Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. <i>Clinical Cancer Research</i> , 2003 , 9, 613-8	12.9	152
93	Rho-stimulated contractility contributes to the fibroblastic phenotype of Ras-transformed epithelial cells. <i>Molecular Biology of the Cell</i> , 1997 , 8, 2329-44	3.5	143
92	VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. <i>Cancer Biology and Therapy</i> , 2006 , 5, 228-33	4.6	141
91	The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. <i>Journal of Biological Chemistry</i> , 1997 , 272, 10608-15	5.4	140
90	Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. <i>Cancer Research</i> , 2002 , 62, 2840-7	10.1	128
89	Differential regulation of EphA2 in normal and malignant cells. <i>American Journal of Pathology</i> , 2003 , 162, 1037-42	5.8	114
88	Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. <i>Oncogene</i> , 2002 , 21, 7690-9	9.2	113
87	A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. <i>Cancer Research</i> , 2008 , 68, 9367-74	10.1	109
86	Efficacy and antivasular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1558-70	9.7	108
85	Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. <i>Journal of Biological Chemistry</i> , 2002 , 277, 39274-9	5.4	108
84	Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. <i>Clinical and Experimental Metastasis</i> , 2003 , 20, 59-68	4.7	107

83	An overview of FDA-approved biologics medicines. <i>Drug Discovery Today</i> , 2015 , 20, 393-8	8.8	104
82	Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. <i>Cancer Gene Therapy</i> , 2004 , 11, 757-66	5.4	102
81	c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. <i>Molecular Cancer Research</i> , 2002 , 1, 79-87	6.6	102
80	An analysis of FDA-approved drugs for infectious disease: antibacterial agents. <i>Drug Discovery Today</i> , 2014 , 19, 1283-7	8.8	101
79	High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. <i>American Journal of Pathology</i> , 2003 , 163, 2271-6	5.8	99
78	Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. <i>Cancer Research</i> , 2003 , 63, 4481-9	10.1	97
77	Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. <i>Neoplasia</i> , 2008 , 10, 1259-67	6.4	94
76	TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. <i>Molecular and Cellular Biology</i> , 2000 , 20, 5828-39	4.8	93
75	Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. <i>Clinical Cancer Research</i> , 2006 , 12, 353-60	12.9	91
74	EphA2 overexpression is associated with angiogenesis in ovarian cancer. <i>Cancer</i> , 2007 , 109, 332-40	6.4	88
73	Loss of 14-3-3sigma in prostate cancer and its precursors. <i>Clinical Cancer Research</i> , 2004 , 10, 3064-8	12.9	85
72	Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 3122-9	6.1	83
71	Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. <i>Cancer Research</i> , 2007 , 67, 3927-35	10.1	77
70	Development of a broad-spectrum antiviral with activity against Ebola virus. <i>Antiviral Research</i> , 2009 , 83, 245-51	10.8	74
69	EphA2 as a target for ovarian cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2005 , 9, 1179-87	6.4	73
68	Predicting the sites of metastases from lung cancer using molecular biologic markers. <i>Annals of Thoracic Surgery</i> , 2001 , 72, 1144-8	2.7	69
67	The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza. <i>Virology</i> , 2009 , 387, 473-81	3.6	66
66	PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 1333-7	12.9	66

65	E-Cadherin Binding Modulates EGF Receptor Activation. <i>Cell Communication and Adhesion</i> , 2003 , 10, 105-118		66
64	Differential EphA2 epitope display on normal versus malignant cells. <i>Cancer Research</i> , 2003 , 63, 7907-12	10.1	65
63	Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. <i>Clinical Cancer Research</i> , 2005 , 11, 226-31	12.9	63
62	Antiviral activity of a small-molecule inhibitor of filovirus infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2152-9	5.9	60
61	An analysis of FDA-approved drugs for oncology. <i>Drug Discovery Today</i> , 2014 , 19, 1831-5	8.8	53
60	EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. <i>Cancer Research</i> , 2003 , 63, 3425-9	10.1	51
59	EphA2 overexpression promotes ovarian cancer growth. <i>Cancer Biology and Therapy</i> , 2008 , 7, 1098-103	4.6	47
58	An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs. <i>Drug Discovery Today</i> , 2014 , 19, 1510-3	8.8	43
57	Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase. <i>Journal of Cellular Biochemistry</i> , 2002 , 85, 714-20	4.7	41
56	E-cadherin binding modulates EGF receptor activation. <i>Cell Communication and Adhesion</i> , 2003 , 10, 105-18		38
55	FGI-104: a broad-spectrum small molecule inhibitor of viral infection. <i>American Journal of Translational Research (discontinued)</i> , 2009 , 1, 87-98	3	35
54	An analysis of original research contributions toward FDA-approved drugs. <i>Drug Discovery Today</i> , 2015 , 20, 1182-7	8.8	30
53	E-cadherin engagement stimulates tyrosine phosphorylation. <i>Cell Adhesion and Communication</i> , 1997 , 4, 425-37		30
52	Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 375-84	4.4	29
51	Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. <i>Neoplasia</i> , 2009 , 11, 509-17, 2 p following 517	6.4	27
50	The engagement of beta1 integrins on promonocytic cells promotes phosphorylation of Syk and formation of a protein complex containing Lyn and beta1 integrin. <i>European Journal of Immunology</i> , 1999 , 29, 1426-34	6.1	27
49	The rise (and decline?) of biotechnology. <i>Drug Discovery Today</i> , 2014 , 19, 1686-1690	8.8	24
48	Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. <i>Journal of Immunology</i> , 2008 , 181, 7721-7	5.3	24

47	EphA2 Induction of Fibronectin Creates a Permissive Microenvironment for Malignant Cells. <i>Molecular Cancer Research</i> , 2004 , 2, 533-540	6.6	24
46	TEL, a putative tumor suppressor, induces apoptosis and represses transcription of Bcl-XL. <i>Journal of Biological Chemistry</i> , 2003 , 278, 46378-86	5.4	23
45	Food and microbiota in the FDA regulatory framework. <i>Science</i> , 2017 , 357, 39-40	33.3	21
44	A mechanism for trabecular meshwork cell retraction: ethacrynic acid initiates the dephosphorylation of focal adhesion proteins. <i>Experimental Eye Research</i> , 1997 , 65, 471-83	3.7	21
43	Trends in pharmaceutical targeting of clinical indications: 1930-2013. <i>Drug Discovery Today</i> , 2014 , 19, 1682-1685	8.8	20
42	An analysis of FDA-approved drugs for neurological disorders. <i>Drug Discovery Today</i> , 2015 , 20, 1040-3	8.8	17
41	Target selection for FDA-approved medicines. <i>Drug Discovery Today</i> , 2015 , 20, 784-9	8.8	17
40	Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. <i>Cancer Biology and Therapy</i> , 2006 , 5, 1357-60	4.6	17
39	2017 in review: FDA approvals of new molecular entities. <i>Drug Discovery Today</i> , 2018 , 23, 1469-1473	8.8	16
38	An overview of FDA-approved vaccines & their innovators. <i>Expert Review of Vaccines</i> , 2017 , 16, 1253-1265	5.2	15
37	Identification of tyrosine phosphorylated adhesion proteins in human cancer cells. <i>Hybridoma</i> , 1998 , 17, 227-35		14
36	2015 in review: FDA approval of new drugs. <i>Drug Discovery Today</i> , 2016 , 21, 1046-50	8.8	13
35	Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway. <i>Molecular Cancer Research</i> , 2003 , 1, 1070-6	6.6	13
34	An analysis of FDA-approved drugs for inflammation and autoimmune diseases. <i>Drug Discovery Today</i> , 2015 , 20, 920-3	8.8	12
33	2016 in review: FDA approvals of new molecular entities. <i>Drug Discovery Today</i> , 2017 , 22, 1593-1597	8.8	12
32	Workgroup 2: human xenograft models of prostate cancer. <i>Prostate</i> , 1998 , 36, 56-8	4.2	12
31	Analysis of FDA-approved imaging agents. <i>Drug Discovery Today</i> , 2017 , 22, 1077-1083	8.8	11
30	Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry. <i>Cell Chemical Biology</i> , 2016 , 23, 644-53	8.2	10

29	New drug discovery: extraordinary opportunities in an uncertain time. <i>Drug Discovery Today</i> , 2015 , 20, 1288-92	8.8	7
28	Assessing the public landscape of clinical-stage pharmaceuticals through freely available online databases. <i>Drug Discovery Today</i> , 2019 , 24, 1010-1016	8.8	6
27	2018 in review: FDA approvals of new molecular entities. <i>Drug Discovery Today</i> , 2019 , 24, 1710-1714	8.8	6
26	An analysis of FDA-approved drugs for cardiovascular diseases. <i>Drug Discovery Today</i> , 2016 , 21, 1-4	8.8	6
25	CDEK: Clinical Drug Experience Knowledgebase. <i>Database: the Journal of Biological Databases and Curation</i> , 2019 , 2019,	5	6
24	An analysis of FDA-approved drugs for metabolic diseases. <i>Drug Discovery Today</i> , 2015 , 20, 648-51	8.8	6
23	Prescription for Change 2016 ,		6
22	Lost medicines: a longer view of the pharmaceutical industry with the potential to reinvigorate discovery. <i>Drug Discovery Today</i> , 2019 , 24, 382-389	8.8	6
21	An analysis of FDA-approved drugs for pain and anesthesia. <i>Drug Discovery Today</i> , 2015 , 20, 3-6	8.8	4
20	Identification of novel host-oriented targets for Human Immunodeficiency Virus type 1 using Random Homozygous Gene Perturbation. <i>Virology Journal</i> , 2009 , 6, 154	6.1	4
19	Expression and purification of the intact cytoplasmic domain of the human ephrin receptor A2 tyrosine kinase in Escherichia coli. <i>Protein Expression and Purification</i> , 2006 , 47, 210-6	2	4
18	A history of drug development in four acts. <i>Drug Discovery Today</i> , 2015 , 20, 1163-8	8.8	3
17	Sources of innovation: an assessment of intellectual property. <i>Drug Discovery Today</i> , 2015 , 20, 500-4	8.8	3
16	An analysis of FDA-approved drugs for psychiatric disorders. <i>Drug Discovery Today</i> , 2015 , 20, 292-5	8.8	3
15	Function-first approaches to improve target identification in cancer. <i>Future Oncology</i> , 2009 , 5, 617-23	3.6	3
14	Expanding roles for academic entrepreneurship in drug discovery. <i>Drug Discovery Today</i> , 2020 , 25, 1905-1905	8.8	3
13	Sources of innovation for new medicines: questions of sustainability. <i>Drug Discovery Today</i> , 2021 , 26, 240-247	8.8	3
12	2021 in review: FDA approvals of new medicines.. <i>Drug Discovery Today</i> , 2022 ,	8.8	3

11	2014 in review: FDA approval of new drugs. <i>Drug Discovery Today</i> , 2017 , 22, 620-624	8.8	2
10	Post-approval fate of pharmaceutical companies. <i>Drug Discovery Today</i> , 2015 , 20, 170-4	8.8	2
9	NIH Support for FDA-Approved Medicines. <i>Cell Chemical Biology</i> , 2017 , 24, 1315-1316	8.2	2
8	The engagement of β integrins on promonocytic cells promotes phosphorylation of Syk and formation of a protein complex containing Lyn and β integrin 1999 , 29, 1426		2
7	Oh, the Frustration of Antibodies!. <i>ACS Pharmacology and Translational Science</i> , 2020 , 3, 1035-1036	5.9	1
6	2019 in review: FDA approvals of new medicines. <i>Drug Discovery Today</i> , 2020 , 25, 1923-1923	8.8	1
5	2020 in review: FDA approvals of new medicines. <i>Drug Discovery Today</i> , 2021 , 26, 2794-2799	8.8	1
4	A Reconsideration of University Gap Funds for Promoting Biomedical Entrepreneurship. <i>Journal of Clinical and Translational Science</i> , 1-18	0.4	0
3	Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?. <i>ACS Pharmacology and Translational Science</i> , 2020 , 3, 1427-1429	5.9	0
2	Cytometric analysis of cell contact and adhesion. <i>Methods in Cell Biology</i> , 2001 , 63, 599-612	1.8	
1	FDA-Approved Medicines1-19		